SCLX
Scilex Holding Company · NASDAQ
- Market cap
- $12.1M
Scilex Holding Company (SCLX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for SCLX, including 1 market update. The most recent was published Oct 22, 2026.
Financial highlights
Full financials- Revenue, TTM
- $31.61M
- Revenue growth
- -28.5%
- Net income, TTM
- -$464.56M
- Net margin
- -1469.8%
- Cash
- $566.0K
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks22-100%
2026-05-242026-11-15
Mix490d
- Insider1(25%)
- Other1(25%)
- SEC Filings1(25%)
- Market1(25%)
Activity · 52 weeks10058 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- NEWSDataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain TechnologiesProprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni HealthFinal Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® SoftwareNetwork of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet TAMPA, FL / ACCESS Newswire / October 22, 2026 / DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its Einste
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Scilex Holding CompanySCHEDULE 13D/A - Scilex Holding Co (0001820190) (Filed by)
- INSIDERLarge owner Scilex Holding Co disposed of $15,755,000 worth of shares (50,000,000 units at $0.32), decreasing direct ownership by 23% to 163,766,229 units (SEC Form 4)4 - Scilex Holding Co (0001820190) (Reporting)
- SECSEC Form 10-Q filed by Scilex Holding Company10-Q - Scilex Holding Co (0001820190) (Filer)
- PRJP 3E Holdings, Inc. Appoints Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to Board of DirectorsTRENTON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- JP 3E Holdings, Inc. (OTC Markets: JPTE) ("JP 3E Holdings" or the "Company") today announced the appointment of Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to its Board of Directors, effective August 13, 2026. The appointments strengthen JP 3E Holdings' Board with additional experience across public-company leadership, capital markets, life sciences, institutional finance and U.S.-Korea cross-border business. The expanded Board will support JP 3E Holdings as the Company advances its strategic initiatives, including its activities in strategic metals and real-world-asset ("RWA") infrastructure. About the New Directors Henry Ji, Ph.D.Execu
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- INSIDERLarge owner Sclx Stock Acquisition Jv Llc disposed of 500,000 shares, decreasing direct ownership by 34% to 958,263 units (SEC Form 4)4 - Scilex Holding Co (0001820190) (Issuer)
- PRScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Dream Bowl I Meme Coin tokens ("Dream Bowl Tokens") commence trading on the Biconomy Exchange on July 6, 2026. To view the Dream Bowl Tokens now trading on the Biconomy Exchange, please click https://www.biconomy.com/exchange/DREAM1_USDT. Scilex believes that the ability to trade the Dream Bowl Tokens may deliver liquidity
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPPALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced the signing of a binding term sheet with iHolding Group LLP ("iHolding"), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates that iHolding will purchase $100,000,000 of newly issued shares of Scilex common stock. The purchase price for such shares is expected to be $15.00 per share,
- SECScilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Scilex Holding Co (0001820190) (Filer)
- INSIDERLarge owner Scilex Holding Co disposed of 7,034,737 shares (SEC Form 4)4 - Scilex Holding Co (0001820190) (Reporting)
- PROramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetSignificant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
- SECScilex Holding Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026PALO ALTO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced Dream Bowl I Meme Coin tokens ("Dream Bowl Tokens") to list on Biconomy Exchange as early as June 23, 2026. Scilex believes that such listing may deliver liquidity and allow for broad distribution of such tokens for the Participating Holders (as defined below). Biconomy serves more than 10 million users and institutions across 180+ co
- PRScilex Holding Company ("Scilex") Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesPALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today confirmed the previously announced payment date of June 15, 2026 (the "Payment Date") for the dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participating Holders") that held such securities as of the r
- SECSEC Form EFFECT filed by Scilex Holding CompanyEFFECT - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesPALO ALTO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") has set June 15, 2026 as the payment date (the "Payment Date") for the previously announced dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participati
- SECSEC Form S-3 filed by Scilex Holding CompanyS-3 - Scilex Holding Co (0001820190) (Filer)
- SECSEC Form EFFECT filed by Scilex Holding CompanyEFFECT - Scilex Holding Co (0001820190) (Filer)
- PRScilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026PALO ALTO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") approved a dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible equityholders of Scilex (collectively, the "Participating Holders"). The record date for the dividend is June 1, 2026 (the "Record Date"). Th
- SECSEC Form 10-Q filed by Scilex Holding Company10-Q - Scilex Holding Co (0001820190) (Filer)
- SECSEC Form NT 10-Q filed by Scilex Holding CompanyNT 10-Q - Scilex Holding Co (0001820190) (Filer)
SCLX FAQ
10 questionsWhat is the latest news on SCLX?
In the last 30 days Quantisnow tracked 1 wire item for SCLX: 1 market update. The most recent was published on October 22, 2026.What is SCLX revenue?
Scilex Holding Company (SCLX) reported $31.61M of revenue for the twelve months ended Jun 30, 2026. That is down 28.5% from the year before. Revenue for fiscal 2025 was $30.25M.Is SCLX profitable?
No. Scilex Holding Company reported a net loss of $464.56M for the twelve months ended Jun 30, 2026.How much cash and debt does SCLX have?
Scilex Holding Company reported $566.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SCLX stock trade?
Scilex Holding Company (SCLX) is listed on NASDAQ.What sector and industry is SCLX in?
Scilex Holding Company operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Scilex Holding Company go public?
Scilex Holding Company (SCLX) completed its IPO in 2021.What are analysts saying about SCLX?
Scilex Holding Company has had 6 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $22.00 price target on 2025-01-27.What companies are similar to SCLX?
Notable peers in the same industry include PCRX (Pacira BioSciences Inc.), HRTX (Heron Therapeutics Inc.), COLL (Collegium Pharmaceutical Inc.), VRTX (Vertex Pharmaceuticals Incorporated). Compare SCLX side-by-side with any of them on Quantisnow.How can I track SCLX on Quantisnow?
Quantisnow aggregates Scilex Holding Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SCLX to receive live email and push alerts on every new disclosure.